#clesrovimab
Clesrovimab
Monoclonal antibody
Clesrovimab (MK-1654) is a fully human monoclonal antibody designed to prevent respiratory syncytial virus (RSV) infections. Developed by Merck, it is in a phase III trial as of 2023. It works differently than nirsevimab.
Wed 24th
Provided by Wikipedia
This keyword could refer to multiple things. Here are some suggestions:
0 searches
This keyword has never been searched before
This keyword has never been searched for with any other keyword.